Home › Research › Inflammation and the immune system
Influence of Ibuprofen on glycerophospholipids and sphingolipids in context of Alzheimer´s Disease
Juliane Radermacher, Vincent Konrad Johannes Erhardt, Oliver Walzer, Elodie Christiane Haas, Konstantin Nicolas Kuppler, Jill Sven René Zügner, Anna Andrea Lauer, Tobias Hartmann et al.. Biomedicine & Pharmacotherapy, 2025-03-11
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Alzheimer's disease (AD) is a multifactorial disorder associated with neuroinflammation, elevated oxidative stress, lipid alterations as well as amyloid-deposits and the formation of neurofibrillary tangles. Ibuprofen, a globally used analgesic, is discussed to influence disease progression due to its anti-inflammatory effect. However, changes in lipid-homeostasis induced by Ibuprofen have not yet been analyzed. Here we investigate the effect of Ibuprofen on lipid classes known to be associated with AD. Ibuprofen treatment leads to a significant increase in phosphatidylcholine, sphingomyelin and triacylglyceride (TAG) species whereas plasmalogens, which are highly susceptible for oxidation, were significantly decreased. The observed alterations in phosphatidylcholine and sphingomyelin levels in presence of Ibuprofen might counteract the reduced phosphatidylcholine- and sphingomyelin-levels found in AD brain tissue with potential positive aspects on synaptic plasticity and ceramide-induced apoptotic effects. On the other hand, Ibuprofen leads to elevated TAG-level resulting in the formation of lipid droplets which are associated with neuroinflammation. Reduction of plasmalogen-levels might accelerate decreased plasmalogen-levels found in AD brains. Treatment of Ibuprofen in terms of lipid-homeostasis reveals both potentially positive and negative changes relevant to AD. Therefore, understanding the influence of Ibuprofen on lipid-homeostasis may help to understand the heterogeneous results of studies treating AD with Ibuprofen. • SH-SY5Y cells treated with Ibuprofen (IBU) revealed significant lipidome changes with relevance for Alzheimer’s disease (AD). • IBU incubation increased phosphatidylcholine and sphingomyeline levels, that were found to be decreased in AD brains. • Plasmalogens, known for their antioxidant properties, were reduced upon IBU treatment. • Triacylglyceride levels, major component of lipid droplets, accumulating in neurons in AD, were elevated after IBU treatment.
What this study adds
Evidence grade: Low
In laboratory lipid studies, ibuprofen raised some lipids that are low in Alzheimer's brain tissue but also raised triglycerides linked to neuroinflammation and lowered plasmalogens, which are already reduced in Alzheimer's brains. This means ibuprofen's effects on brain lipids are mixed, with both potentially helpful and potentially harmful changes, so it cannot be assumed to slow or prevent the disease.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Radermacher, J., Erhardt, V. K. J., Walzer, O., Haas, E. C., Kuppler, K. N., Zügner, J. S. R., et al. (2025). Influence of Ibuprofen on glycerophospholipids and sphingolipids in context of Alzheimer´s Disease. Biomedicine & Pharmacotherapy. https://doi.org/10.1016/j.biopha.2025.117969
Vancouver
Radermacher J, Erhardt VKJ, Walzer O, Haas EC, Kuppler KN, Zügner JSR, et al. Influence of Ibuprofen on glycerophospholipids and sphingolipids in context of Alzheimer´s Disease. Biomedicine & Pharmacotherapy. 2025. doi:10.1016/j.biopha.2025.117969. PMID: 40073745.
BibTeX
@article{radermacher2025-40073745,
author = {Radermacher, Juliane and Erhardt, Vincent Konrad Johannes and Walzer, Oliver and Haas, Elodie Christiane and Kuppler, Konstantin Nicolas and Zügner, Jill Sven René and Lauer, Anna Andrea and Hartmann, Tobias and others},
title = {{Influence of Ibuprofen on glycerophospholipids and sphingolipids in context of Alzheimer´s Disease}},
journal = {Biomedicine \& Pharmacotherapy},
year = {2025},
doi = {10.1016/j.biopha.2025.117969},
pmid = {40073745},
url = {https://doi.org/10.1016/j.biopha.2025.117969}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Alzheimer's disease (AD) is a multifactorial disorder associated with neuroinflammation, elevated oxidative stress, lipid alterations as well as amyloid-deposits and the formation of neurofibrillary tangles.
- Here we investigate the effect of Ibuprofen on lipid classes known to be associated with AD.
- Ibuprofen treatment leads to a significant increase in phosphatidylcholine, sphingomyelin and triacylglyceride (TAG) species whereas plasmalogens, which are highly susceptible for oxidation, were significantly decreased.
- On the other hand, Ibuprofen leads to elevated TAG-level resulting in the formation of lipid droplets which are associated with neuroinflammation.
- Therefore, understanding the influence of Ibuprofen on lipid-homeostasis may help to understand the heterogeneous results of studies treating AD with Ibuprofen. • SH-SY5Y cells treated with Ibuprofen (IBU) revealed significant lipidome changes with relevance for Alzheimer’s disease (AD). • IBU incubation increased phosphatidylcholine and sphingomyeline levels, that were found to be decreased in AD brains. • Plasmalogens, known for their antioxidant properties, were reduced upon IBU treatment. • Triacylglyceride levels, major component of lipid droplets, accumulating in neurons in AD, were elevated after IBU treatment.
Why it matters
In laboratory lipid studies, ibuprofen raised some lipids that are low in Alzheimer's brain tissue but also raised triglycerides linked to neuroinflammation and lowered plasmalogens, which are already reduced in Alzheimer's brains. This means ibuprofen's effects on brain lipids are mixed, with both potentially helpful and potentially harmful changes, so it cannot be assumed to slow or prevent the disease.
Study details
- Evidence strengthLow
How this study scored 35/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Biomedicine & Pharmacotherapy) |
| Journal's citation record | 2 / 4 | Biomedicine & Pharmacotherapy: journal h-index 227 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 1 / 7 | Cited 3 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 1.0 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 2 / 6 | Cited 1.6× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 1 / 4 | Cited 3 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Marcus O.W. Grimm: h-index 42 (OpenAlex, whole career) |
| Institution's track record | 0 / 3 | Saarland University: institution h-index 560 (OpenAlex) |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40073745) |
| Free to read | 2 / 2 | Free to read |
| Total | 35 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1016/j.biopha.2025.117969
- PubMed: 40073745
- Original source →
- Free full text: Biomedicine & Pharmacotherapy →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Inflammation and the immune system from nearby years
Also tagged “precursor”
1,337 studies in the library carry the topic tag “precursor”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,337 tagged studies.